Fig. 4
SARS-CoV-2 anti-S1 IgG antibody titers for infected vs. non-infected cancer patients for different time periods. Boxplots represent log10-transformed SARS-CoV-2 anti-S1 IgG antibody titers for cancer patients infected with SARS-CoV-2 (blue) and non-infected patients (red) during the indicated time periods. A two-sided p-value < 0.05 after Bonferroni-Holm correction for multiple testing was considered statistically significant: *p < 0.05. (A) SARS-CoV-2 anti-S1 IgG antibody titers between 28 days after second vaccine dose and prior to first booster dose (time period E). (B) SARS-CoV-2 anti-S1 IgG antibody titers between first booster administration and 28 days afterwards (time period F). (C) SARS-CoV-2 anti-S1 IgG antibody titers between 28 days and 6 months after first booster dose (time period G). (D) SARS-CoV-2 anti-S1 IgG antibody titers between 6 months after first booster dose and second booster administration (time period H). (E) SARS-CoV-2 anti-S1 IgG antibody titers between 28 days after second booster administration and the end of the study (time period I).
